Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.61 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119609 | 0.94 | PPARG (0.68) | PPARG | |
| SCHEMBL5112960 | 0.93 | PPARG (0.58) | PPARGPTGER1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5114265 | 0.88 | PPARG (0.60) | PPARG | |
| SCHEMBL5113004 | 0.87 | PPARG (0.66) | PPARGP2RX3 | |
| SCHEMBL5114862 | 0.86 | PPARG (0.67) | PPARG | |
| SCHEMBL5121479 | 0.85 | PPARG (0.49) | PPARG | |
| SCHEMBL5120001 | 0.84 | PPARG (0.56) | PPARG | |
| SCHEMBL5112484 | 0.84 | PPARG (0.54) | PPARGPTGER1 | |
| SCHEMBL5109947 | 0.83 | PPARG (0.70) | PPARG | |
| SCHEMBL5114191 | 0.82 | PPARG (0.88) | PPARGP2RX3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885P2RX3 746/4885PTGER1 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.